![[Bio USA] Samsung Biologics doubles down on CDMO leadership after biosimilar spinoff](/_next/image?url=https%3A%2F%2Fwimg.heraldcorp.com%2Fnews%2Fcms%2F2025%2F06%2F18%2Fnews-p.v1.20250618.21e8febe0361403eb6fc8a1d8bf30695_T1.jpg&w=3840&q=100)
[Bio USA] Samsung Biologics doubles down on CDMO leadership after biosimilar spinoff
BOSTON — Samsung Biologics CEO John Rim unveiled an ambitious road map to strengthen the company's position as a global leader in CDMO during a press conference held on the sidelines of this year's Bio USA on Tuesday, emphasizing sharpened focus, expanded capabilities and accelerated global expansion.
At the center of the announcement was Samsung Biologics' recent corporate split, which fully separates its CDMO operations from Samsung Bioepis, its former biosimilar arm. Rim described the move as a milestone that allows Samsung Biologics to operate as a 'pure-play CDMO.'
'By becoming a stand-alone CDMO, we can focus entirely on our core mission—delivering best-in-class biomanufacturing and development services while enhancing transparency and trust with our global partners,' said Rim. 'This also enables investors to evaluate each business based on its own strategic value and growth potential.'
The strategic restructuring is expected to unlock hidden value within Samsung's portfolio and further elevate shareholder value by making the distinct business models more visible and investable.
Highlighting strong sector fundamentals, Rim pointed to rising global demand for biologics manufacturing, driven by expanding indications for blockbuster drugs and the development of new modalities, such as ADCs, AOCs and gene therapies.
"Following the corporate split, our overseas clients responded positively, as it eliminated any perceived conflicts of interest," Rim emphasized. "Samsung Biologics will continue to fuel its growth by advancing its three core pillars: Geographic expansion, increased capacity and diversification of modalities."
According to market research firm Frost & Sullivan, the global biologics CDMO market is projected to grow at a CAGR of 15 percent from $21.8 billion in 2024 to $43.9 billion in 2029. Despite some pharma companies announcing in-house capacity expansions, CMO outsourcing demand continues to rise as pharma remains cautious with internal investments.
"Just three years ago, there were industry-wide concerns about potential oversupply in the CDMO market. However, we've since witnessed consistent double-digit growth, and with continued category expansion — particularly in the antibody segment — the outlook for CDMOs appears stronger than ever," Rim explained.
Samsung Biologics is doubling down on its global client outreach.
The company currently serves 17 of the top 20 global pharmaceutical companies and has intensified efforts to expand its reach among the top 40. In addition to sales offices in New Jersey and Boston, it opened a Tokyo office earlier this year to improve engagement with Asia-based clients.
'Our global clients trust Samsung for both scale and speed. As we expand geographically and technologically, we are committed to offering localized support with global excellence,' Rim emphasized.
As of June 2025, Samsung Biologics has secured five new contracts this year totaling 3.35 trillion won ($2.58 billion), surpassing 60 percent of last year's full-year bookings of 5.4 trillion won. The company's cumulative order value since inception now stands at $18.7 billion.
'Despite macroeconomic uncertainties, our pipeline remains strong, and we maintain our full-year revenue guidance of 20–25 percent growth,' said Rim. 'We expect to see continued momentum as we deepen global partnerships and reinforce our role as a full-service biopharma enabler.'
Meanwhile, Samsung Biologics is investing heavily in modality diversification to meet evolving customer needs. It recently launched a dedicated facility for ADCs, supporting full development and GMP production, with capabilities ranging from 2 milliliters to 500 liters. The company plans to introduce a dedicated ADC DP line by Q1 2027, completing an end-to-end solution within its Songdo site in Incheon.
'The more competitors there are, the more positive impact it has on patients, so we fully welcome competition. Of course, when it comes to winning contracts, we believe we possess the best internal competitiveness. We are confident that not only our infrastructure but also the strength of our workforce are our greatest assets.'
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Korea Herald
14 hours ago
- Korea Herald
Talks launched to set date for 1st Lee-Trump summit
Seoul and Washington have launched discussions to set a date for a summit between President Lee Jae Myung and US President Donald Trump, South Korea's Foreign Minister said Friday. The latest talks follow US President Donald Trump's remark that his first summit with Lee would take place in the White House 'within two weeks,' shared the previous day via Truth Social. "(The two sides) are coordinating to set a date (for the summit)," Cho said during a meeting with South Korean correspondents in Washington. Cho added that the 'content' of the summit would be jointly discussed and planned between Seoul and Washington 'at the working level.' Ahead of his meeting with the press, Cho held his first talks with his counterpart, US Secretary of State Marco Rubio. The top diplomats discussed key issues, including the trade deal reached between Seoul and Washington, and the allies' security commitment to defend peace on the Korean Peninsula against North Korean threats, according to Cho and the US Department of State. On Thursday, the two countries reached a trade agreement in which the US will impose 15 percent tariffs on South Korean goods, down from the initially proposed 25 percent. In exchange, South Korea would invest $350 billion in several US economic sectors. A high-ranking Seoul official, requesting anonymity, told reporters that the discussions for the summit are still at an early stage. '(So far,) the discussions have addressed only the potential dates (for the summit) -- it is expected to take a little more time,' the official said. The official added that it would be difficult to confirm at the moment whether the summit would take place within the two-week timeframe mentioned by Trump. However, Seoul and Washington agree that the summit agenda should include ways to develop and steer the decadesold alliance towards a 'comprehensive' and 'future-oriented' partnership, the official said. As for Trump's possible attendance at the Asia-Pacific Economic Cooperation summit set to take place in the South Korean city of Gyeongju from Oct. 31 to Nov. 1, Rubio told Cho that he is fully aware of the event and plans to actively review the matter, Seoul's Foreign Ministry said. The White House has not announced whether Trump will join. South Korea's presidential office last month sent out invitation letters to the leaders of the 21 APEC member economies, including the US, China, Russia and Japan. Cho also told reporters that he was able to deliver and explain the Lee administration's foreign policy stance to officials in Washington and that both sides agreed to work toward alleviating tensions on the peninsula. '(Seoul and Washington) will make comprehensive efforts to move in the direction of alleviating tensions on the Korean Peninsula,' Cho said. '(South Korea) plans to closely coordinate with the US in the process and pursue (that goal) with US support.' With the Lee administration seeking to improve inter-Korean relations, there have been discussions in Seoul in recent days about adjusting the annual South Korea-US joint military exercise Ulchi Freedom Shield, scheduled for mid-August. Seoul's Unification Minister Chung Dong-young told reporters on Monday he plans to suggest such adjustments to Lee, but the Defense Ministry said the following day that no changes have yet been made to the scheduled drills. North Korean leader Kim Jong-un's powerful sister, Kim Yo-jong, recently denounced Lee by saying that he 'is no different from his predecessor in blindly adhering to the South Korea-US alliance' in a statement released through Pyongyang's state media. She denounced the South Korea-US joint military exercises as "aggressive," and claimed that the decadesold allies will attempt to blame the "deteriorating" security situation on Pyongyang. The North has routinely condemned the joint military drills as a provocation and a rehearsal for invasion.
Korea Herald
14 hours ago
- Korea Herald
SK hynix overtakes Samsung to lead global memory market for 1st time with HBM surge
SK hynix has claimed the top spot in the global memory chip market for the first time, overtaking long-time leader Samsung Electronics on the back of its dominance in high bandwidth memory chips, the highly lucrative artificial intelligence products. According to market tracker Counterpoint Research on Thursday, SK hynix recorded 21.8 trillion won ($15.6 billion) in memory sales, including both DRAM and NAND products, in the April-June period, narrowly surpassing Samsung's 21.2 trillion won. SK hynix also hit an all-time high quarterly operating profit of 9.2 trillion won from its chip sales alone. This is almost double Samsung's total operating profit of 4.6 trillion won across all segments, including smartphones, consumer electronics, memory, logic chips and contract chipmaking. SK hynix' rise is largely attributed to its leadership in the fast-growing HBM memory chips, a critical component for AI processors. Since becoming a key supplier of cutting-edge HBM chips to Nvidia, the world's largest graphic processing unit supplier, the memory chip maker has seen a consistent increase in profitability, while Samsung's earnings have been on a downward trend, reflecting its weaker position in the HBM market. According to Counterpoint's Memory Tracker, Samsung's share of HBM shipments plummeted to 17 percent in the second quarter of this year from 41 percent a year earlier, trailing behind SK hynix and US-based Micron Technology. SK hynix accounted for 62 percent of global HBM shipments, followed by Micron with a 21 percent share. The decline in Samsung's share was attributed in part to US export restrictions to China introduced earlier this year, which limited the company's sales channels. As SK hynix is seeing soaring sales by supplying Nvidia with its most advanced 8-layer and 12-layer HBM3E products, Samsung is struggling to pass the GPU maker's qualification tests and remains largely dependent on older-generation HBM3 chips for its HBM sales. 'The good news is that Samsung's HBM sales appear to have bottomed out in (the first quarter of) 2025 and are showing signs of recovery in (the second quarter),' Choi Jeong-ku, Counterpoint Research analyst, said. 'To regain lost market share, however, it is critical for Samsung to diversify its HBM3E customer base and pass Nvidia's stringent quality tests.' Choi also noted that Samsung should focus on achieving stable yield levels to supply next-generation HBM4 for Nvidia's upcoming Rubin platform. "Considering the recent announcement that Samsung Foundry has won orders from Tesla, there is growing expectation for an overall improvement in Samsung's future performance," Choi added.
Korea Herald
a day ago
- Korea Herald
After tariff deal reprieve, Samsung braces for new trade rules
Chip earnings slump to 6-quarter low, but recovery expected on AI, Tesla orders Samsung Electronics said Thursday it is closely monitoring the upcoming decision by the US Department of Commerce regarding semiconductor-related trade regulations, despite an easing in uncertainty following tariff negotiations between South Korea and the US on the same day. During a conference call following its second-quarter earnings announcement, the tech giant said the decision expected in mid-August pertains to the Section 232 investigation under the US Trade Expansion Act, which covers semiconductor and finished products, including smartphones, tablets, PCs and monitors. 'We are keeping a close watch on the outcome of the Section 232 investigation, as it may have implications beyond chips,' a Samsung Electronics official said. 'We have been actively presenting our views throughout the investigation process and have maintained close communication with relevant authorities in both countries.' Samsung said it is preparing a multi-layered response strategy to minimize business risks and seize potential opportunities, depending on the outcome of bilateral discussions between Seoul and Washington. Meanwhile, Samsung highlighted a recent $16.5 billion order secured from Tesla as a 'milestone' that demonstrates the competitiveness of the company's advanced process technologies. It said the deal is expected to pave the way for additional orders from other major clients, contributing to stable operations at its US-based Taylor plant. Samsung has been pushing ahead with the construction of a new chip fabrication plant in Taylor, Texas, with the goal of fulfilling high-value chip contracts from diverse US clients. The plant is slated to begin full-scale operations next year. For 2025, the company said investment in the Taylor facility will remain within this year's capex range but will increase next year. The company also announced that it has completed approval for transitioning its 1c DRAM using a 10-nanometer process to pilot mass production. Based on this, it has finalized the development of its sixth-generation HBM chips, known as HBM4, and has begun shipping samples to major clients. 'Our HBM4 applies advanced logic processes to the base die and features an optimized design, resulting in improvements in performance and energy efficiency compared to the previous generation, HBM3E,' a Samsung Electronics official said. 'We plan to ramp up timely supply in line with the full-scale demand for HBM4 expected next year.' Earlier in the day, Samsung announced its preliminary earnings for the second quarter, reporting an operating profit of 4.68 trillion won ($3.36 billion), down 55.2 percent from a year earlier. Net income fell 48 percent to 5.12 trillion won, while sales rose slightly by 0.67 percent to 74.6 trillion won. These figures fell short of market expectations. According to financial data provider FnGuide, consensus estimates had forecast 6.18 trillion won in operating profit and 76.2 trillion won in sales. Samsung's Device Solutions division, which oversees the semiconductor business, posted 27.9 trillion won in sales and 400 billion won in operating profit — its lowest since a 2 trillion won loss in the fourth quarter in 2023. Despite growth in high-value memory and foundry sales, profitability was impacted by inventory-related charges and US sanctions affecting the non-memory business. The Device eXperience division, which handles mobile and consumer electronics, recorded 43.6 trillion won in revenue and 3.3 trillion won in operating profit. The decline was attributed to reduced Galaxy S25 smartphone sales and intensified competition in the TV market, resulting in a 16 percent drop in revenue and a 1.4 trillion won fall in profit compared to a year ago. Looking ahead, Samsung forecasts a gradual rebound in the third quarter as one-off costs subside, although lingering tariff uncertainties and global economic slowdowns may pose challenges. 'While global trade uncertainties and geopolitical risks raise concerns about slower growth, we expect momentum in the artificial intelligence and robotics industries to gradually drive recovery in the IT sector,' a Samsung Electronics official said.
